We also show that mIHC combined with DIA is an efficient approach to assess the prognostic value of CDX2 protein expression, highlighting the potential clinical utility of this technology to assess nuclear and cytoplasmic markers in a more standardized fashion, in line with results in esophageal cancer [33], breast cancer [34], and colorectal cancer [35]. This evidence concerns the gene CDX2 and breast cancer.